Company intelligence / Profile preview
Kanvas Biosciences
Princeton, New Jersey, United Stateskanvasbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Kanvas Biosciences is advancing its lead candidate KAN-001 toward IND filing in 2025. KAN-001 is designed to improve the efficacy of immunotherapy in the treatment of solid organ cancer.
- Therapeutic areas
- Oncology
- Modalities
- Live biotherapeutic products (LBPs)Microbial consortia
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Partnerships with biotechnology and pharmaceutical companies (specific names not provided)
Beyond the preview
Go deeper on Kanvas Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kanvas Biosciences.